Engineered immune cells take aim at Hard-to-Treat cancers
NCT ID NCT06767046
First seen Feb 01, 2026 · Last updated May 23, 2026 · Updated 16 times
Summary
This early study tests a new treatment for people with advanced colorectal, pancreatic, or lung cancer that has a specific change in the KRAS gene (called G12V). The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goals are to check the treatment's safety and see if it can shrink tumors. Only 8 people are taking part, and all have already tried standard treatments without success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Capital Medical University Affiliated Beijing Ditan Hospital
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.